US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Maplight Therapeutics (MPLT): Schizophrenia and Alzheimer’s Disease Biotech Sets Terms for IPO

Maplight Therapeutics (MPLT): Clubby Biotech Deal Anticipated as IPO Market Pushes Ahead

MapLight Therapeutics Inc. (MPLT): Oversubscribed Neuroscience IPO Launches with a Bright Start

IPOs and Secondary Offerings

Equity Capital Markets

MapLight Therapeutics / Equity Capital Markets

<ul>
<li>The company that describes itself as a biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system.</li>
<li>Morgan Stanley, Jefferies, Leerink Partners, Stifel are the bookrunners on this IPO.</li>
<li>Their lead product candidate, ML-007C-MA, is currently in a Phase II trial.</li>
</ul>


The company that describes itself as a biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system.
Morgan Stanley, Jefferies, Leerink Partners, Stifel are the bookrunners on this IPO.
Their lead product candidate, ML-007C-MA, is currently in a Phase II trial.


Maplight Therapeutics (MPLT): Peeking at the IPO Prospectus of Biotech Treating CNS Diseases